Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628220 | 1.00 | KDM4E (0.63) | KDM4ETP53TSHREPHX2KMT2A | |
| SCHEMBL30087601 | 0.90 | KDM4E (0.58) | KDM4ETP53TSHREPHX2KMT2A | |
| SCHEMBL17420707 | 0.88 | KDM4E (0.61) | KDM4EKMT2AALDH1A1LMNAGAA | |
| SCHEMBL30628313 | 0.88 | KDM4E (0.61) | KDM4EKMT2AALDH1A1LMNAGAA | |
| SCHEMBL17420459 | 0.86 | KDM4E (0.54) | KDM4ETP53TSHREPHX2KMT2A | |
| SCHEMBL25376588 | 0.85 | KDM4E (0.60) | KDM4EEPHX2ALDH1A1GAALTA4H | |
| SCHEMBL17420455 | 0.85 | KDM4E (0.56) | KDM4ETP53TSHREPHX2KMT2A | |
| SCHEMBL18231431 | 0.81 | KDM4E (0.58) | KDM4ETP53TSHREPHX2KMT2A | |
| SCHEMBL11937211 | 0.80 | ALDH1A1 (0.59) | KDM4ETP53TSHREPHX2KMT2A | |
| SCHEMBL4698008 | 0.79 | KDM4E (0.70) | KDM4ETP53TSHREPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-28 | — | — | US | disclosed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-106660991-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | disclosed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-01-25 | — | — | US | disclosed |
| US-9808451-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3166937-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2017-01-12 | — | — | US | disclosed |
| US-9499514-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KDM4E 1196/4885TP53 11/4885TSHR 4516/4885 |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KDM4E 1196/4885TP53 11/4885TSHR 4516/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | KDM4E 1196/4885TP53 11/4885TSHR 4516/4885 |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KDM4E 1196/4885TP53 11/4885TSHR 4516/4885 |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KDM4E 1196/4885TP53 11/4885TSHR 4516/4885 |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KDM4E 1196/4885TP53 11/4885TSHR 4516/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KDM4E 1196/4885TP53 11/4885TSHR 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.